Selective N1-Alkylation of 1,3-Dibenzoyluracils: One-Pot Way to N1-Monosubstituted Uracil Derivatives
摘要:
A new method for synthesis of N(-)(1)monosubstituted uracils and 5- and 6-methyluracil derivatives was developed. It consists in the selective N-1-deprotection of N-1,N-3-dibenzoyluracils in anhydrous dimethylformamide in the presence of potassium carbonate at room temperature and subsequent N-1-alkylation by allyl, benzyl or phenacyl type halides or by primary alcohols toluenesulfonates conducted one pot without isolation of the intermediates. Final N-3-debenzoylation by aqueous-alcoholic solution of ammonia affords the corresponding N-1-monosubstituted uracil derivatives with overall yields of 52-84%.
Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
申请人:Ammenn Jochen
公开号:US20050272718A1
公开(公告)日:2005-12-08
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
本发明涉及一种式 I 的黑色素浓缩激素拮抗剂化合物:(I);或其药学上可接受的盐、溶液剂、对映体或原药,可用于治疗、预防或改善与肥胖及相关疾病有关的症状。
Nair; Peacock, Journal of the Indian Chemical Society, 1935, vol. 12, p. 318,321
作者:Nair、Peacock
DOI:——
日期:——
MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES
申请人:ELI LILLY AND COMPANY
公开号:EP1505968A1
公开(公告)日:2005-02-16
US7229987B2
申请人:——
公开号:US7229987B2
公开(公告)日:2007-06-12
[EN] MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES<br/>[FR] COMPOSES MULTICYCLIQUES QUE L'ON UTILISE COMME ANTAGONISTES DE L'HORMONE DE CONCENTRATION DE MELANINE DANS LE TRAITEMENT DE L'OBESITE ET DU DIABETE
申请人:LILLY CO ELI
公开号:WO2003097047A1
公开(公告)日:2003-11-27
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I);or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.